← All trials
NCT00226759
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2004
- Primary completion
- Sep 30, 2010
- Completion date
- Mar 31, 2011
- First posted
- Sep 27, 2005
- Last posted
- Oct 12, 2012
- Enrollment
- 321
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Omeros CorporationLead sponsor
- Omeros CorporationStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.